Back to Jason WhitePage
|
|
Dr JASON D. WHITE
|
|
|
Publications
|
|
|
2008
|
White JD, Vuocolo T, McDonagh M, Grounds MD, Harper G, Cockett NE, Tellam R. (2008) Cellular analysis of the Callipyge phenotype through skeletal muscle development; association of Dlk1 with developing satellite cells. Differentiation. 76:283-298 |
|
2006
|
Shavlakadze T, White JD, Davies M, Grounds MD, Boswell JM, Burt DW, Asante EA, Tomas FM, Goddard C. (2006) Rsk?-actin/hIGF-I transgenic mice with increased IGF-I levels in skeletal muscle and blood: impact on regeneration, denervation, atrophy and muscular dystrophy. Growth Hormone and IGF Research Jun;16(3):157-73. |
|
2005
|
Grounds MD, Sorokin L, White J. (2005) Strength at the extracellular-muscle interface. Scandinavian Journal of Medicine & Science in Sports. Dec;15(6):381-91. |
| Shavlakadze T, White J, Davies M, Hoh JYF, Grounds MD. (2005) Insulin-like growth factor-1 slows the rate of denervation induced skeletal muscle atrophy. Neuromuscular Disorders. 15: 139-146. | |
|
2004
|
Shavlakadze T, White J, Rosenthal NA, Grounds MD. (2004) Targeted expression of insulin-like growth factor-I reduces the necrosis of dystrophic mdx muscle. Molecular Therapy. Nov;10(5):829-43. |
| Shavlakadze T, White JD, Davies M, Grounds MD. (2004) Early regeneration of whole skeletal muscle grafts is unaffected by over-expression of IGF-1 in MLC/mIGF-1 transgenic mice. J. Histochem Cytochem. 52:873-883. | |
|
2003
|
White J, Grounds MD (2003) Harnessing the therapeutic potential of myogenic stem cells. (Invited review). Cytotechnology. 41:153-164. |
|
2002
|
White Jason D, Davies Marilyn, McGeachie John and Grounds Miranda D (2002). An evaluation of Leukaemia Inhibitory Factor as a potential therapeutic agent for the treatment of muscle disease. Neuromuscular Disorders. 12(10): 909-916. |
| Miranda D. Grounds, Jason D. White, Nadia Rosenthal and Marie A. Bogoyevitch. The Role of Stem Cells in Skeletal and Cardiac Muscle Repair. J. Histochem Cytochem. 50: 589-610. | |
| Jason D. White, Rachel Collins, Royce Vermeulen, Marilyn Davies and Miranda D. Grounds. The role of p53 in vivo during skeletal muscle post-natal development and regeneration: studies in p53 knockout mice. International J. Develop. Biol. 46: 577-582 | |
|
2001 |
Jason D. White, Marilyn Davies and Miranda D. Grounds. Leukaemia Inhibitory Factor and the Extracellular Matrix: in vitro and in vivo studies in skeletal muscle. Submitted to Experimental Cell Research 306: 129-141. |
| Julia Huijbregets, Jason D. White and Miranda D. Grounds. The Absence of MyoD in Regenerating Skeletal Muscle Affects the Expression Pattern of Basement Membrane, Interstitial Matrix and Integrin Molecules. Acta Histochemica. 103(4): 379-396 | |
|
2000
|
Jason D. White, John J. Bower,. John B. Kurek and. Lawrie Austin. Leukaemia inhibitory factor increases regeneration in skeletal muscles after myoblast transplantation. Muscle & Nerve. 24; 695-697. |
| Austin L., Bower J.J., Bennett T.M,. White J.D., W Barnard and G Lynch.(2000) Leukaemia inhibitory factor (LIF) reverses muscle fiber degeneration in the mdx mouse. Muscle & Nerve. 23(11):1700-1705. | |
| Jason D. White, Amelia Scaffidi,. Marilyn Davies, John McGeachie,. Michael A Rudnicki and Miranda D Grounds. Myotube formation is delayed but not prevented in MyoD deficient skeletal muscle: Studies in whole muscle grafts. Journal of Histochemistry and Cytochemistry. 48(11):1531-1544. | |
|
1998
|
Kurek J.B., Bower J.J., White J.D., Muldoon C.M. and Austin L. (1998). Leukaemia inhibitory factor and other cytokines as factors influencing regeneration of skeletal muscle. Basic and Applied Myology. 8(5):347-360. |
| White J., Bower J., Kurek J., Muldoon C. and Austin L. (1998). Muscular dystrophy gene therapy. Today's Life Science. 10(5):18-21. | |
|
1997
|
Bower J.J., White J.D., Kurek J.B., Muldoon C. and Austin L. (1997). The role of growth factors in myoblast transfer therapy. Basic and Applied Myology. 7(3&4):177-188. |
| Esdale W., Walker T., White J., DeCruz E.E. and Burton M.A. (1997). The efficacy of sustained release doxorubicin for hepatic micrometastases. Clinical and Experimental Metastases. 15:1-7. | |
|
1996
|
Walker T.L., White J.D., Esdale W.J., Burton M.A. and DeCruz E.E. (1996). Tumour cells surviving in vivo cisplatin chemotherapy display elevated c-myc expression. British Journal of Cancer. 73:610-614. |
